hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 21:58:57 - browse：62139

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Grail's uphill battle for Medicare to cover its cancer screening test

focus

WSS

It's time to take a new tack for treating Alzheimer's

Britney Spears to release memoir, 'The Woman In Me,' later this year

New chart reveals military’s vast involvement in Operation Warp Speed

Sickle cell gene therapy cures need to be accessible in Africa

Inflation cooled significantly in June, bringing price hikes close to normal levels

'The View' co

leisure time

hotspot

The next ALS data readout — overdue but important

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hey, doctors: Don't be no

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

After affirmative action ruling, medical educators look to 'holistic review'

How are insurers handling Leqembi and related scans?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Trump Organization, Michael Cohen agree to settle million

explore

It's time to take a new tack for treating Alzheimer's

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

Superbugs, antibiotic resistance get scrutiny in congress

Why Marc Tessier

Listen: BridgeBio's big week & Lilly's Alzheimer's data

Hey, doctors: Don't be no

hotspot

focus

explore

hotspot